Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 10, 2010, Pages 1057-1063

  Cicero, Theodore J ^a   Ellis, Matthew S ^a   Paradis, Alethea ^a   Ortbal, Zachary ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Opioid agonists; Abuse; Fentanyl; Opioid exposure; Pain management

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OXYCODONE; TRAMADOL;

ADULT; ANALGESIC AGENT ABUSE; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; EUPHORIA; FEAR; FEMALE; HEALTH CARE PERSONNEL; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PAIN; PHARMACOEPIDEMIOLOGY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; ANALGESICS, OPIOID; DATA COLLECTION; FEMALE; FENTANYL; HUMANS; MALE; OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID, MU; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 78751623078     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1989     Document Type: Article

References (30)

1. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoproteincompetent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 2007; 323(1): 346-355. Epub 2007 Jul 23.
2. Sirohi S, Dighe SV, Walker EA, Yoburn BC. The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav 2008; 91(1): 115-120.
3. Portenoy RK, Payne R, Passik SK, et al. Substance Abuse: A Comprehensive Textbook, 4th edn. Lippincott, Williams &Wilkens: Philadelphia, 2004; Acute and Chronic Pain; 863-904.
4. Melzack R. The tragedy of needless pain. Sci Am 1990; 262: 27-33.
5. Hursh SR, Winger G. Normalized demand for drugs and other reinforcers. J Exp Anal Behav 1995; 64, 373-384.
6. Pchelintsev MV, Gorbacheva EN, Zvartau EE. Simple methodology of assessment of analgesics' addictive potential in mice. Pharmacol Biochem Behav 1991; 39, 873-876.
7. Broadbear JH, Winger G, Woods JH. Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology (Berl) 2004; 176(3-4): 398-406. Epub 2004 Apr 28.
8. Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM. Comparative abuse liability of intravenously administered remifentanil and fentanyl. J Clin Psychopharmacol 2000; 20(6): 597-606.
9. Sellers EM, Schuller R, Romach MK, Horbay GL. Relative abuse potential ofopioid formulations in Canada: a structured field study. J Opioid Manag 2006; 2(4): 219-227.
10. Greenwald MK. Behavioral economic analysis of drug preference using multiple choice procedure data. Drug Alcohol Depend 2008; 93(1-2): 103-110. Epub 2007 Oct 18.
11. Griffiths R, Bigelow G, Ator N. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003; 70, 241-s54.
12. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283(13): 1710-1714.
13. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med 2004; 5(1): 59-65.
14. Cicero TJ, Inciardi JA, Surratt H. Trends in the use and abuse of branded and generic extended release oxycondone and fentanyl products in the United States. Drug Alcohol Depend 2007; 91(2-3): 115-120. Epub 2007 Jun 21.
15. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6(10): 662-672.
16. Fodale V, Mafrica F, Santamaria L, Coleman JJ. Killer fentanyl: is the fear justified? Expert Opin Drug Saf 2008; 7(3): 213-217.
17. Clark HW. Substance Abuse and Mental Health Services Administration. Center for Mental Health Services/Center for Substance Abuse Prevention/Center for Substance Abuse Treatment. June 2006.
18. Joseph D. Drugs of Abuse. U.S. Department of Justice/Drug Enforcement Administration. 2005.
19. Bryson E, Silverstein J. Addiction and substance abuse in anesthesiology. Anesthesiology 2008; 109(5): 905-917.
20. Domino K, Hornbein T, Polissar N, et al. Risk factors for relapse in health care professionals with substance use disorders. JAMA 2005; 293(12): 1513-1515.
21. Baldisseri MR. Impaired healthcare professional. Crit Care Med 2007; 35: S106-S116.
22. Maher-Brisen P. Addiction: an occupational hazard in nursing. AMJ Nurse 2007; 107(8): 78-79.
23. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672.
24. Cicero TJ, Surratt H, Inciardi JA. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007; 16(8): 827-840.
25. Cicero TJ. Prescription drug abuse and its relationship to pain management. Adv Pain Manag 2008; 2(1): 17-29.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association: Washington, DC, 1994.
27. Fagerstrom KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978; 3: 235-241.
28. Rosenblum A, Marsch L, Joseph H, Portenoy R. Opioids and the treatment of chronic pain: controversies, current status and future directions. Exp Clin Psychopharmacol 2008; 16(5): 405-416.
29. Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008; 24(6): 528-535.
30. Pooler D, Sheheen F, Davidson J. Professional impairment: a history and one state's response. J Addict Dis 2009; 28(2): 113-123.